[Diagnosis of urethritis in men. A 3-year review].
OBJECTIVE
The aim of this study is to know the prevalence and tendency of microorganisms producing urethritis, in men, in the City Centre of Madrid.


METHODS
Cross-sectional study. The urethral samples of 1.248 men were analyzed, for 3 years. The samples were studied for: GRAM stain, when secretion exists; culture in habitual plates; detection of C. trachomatis, U. urealyticum and M. hominis, when there was suspicious, study of T. vaginalis and when suspicious injuries exist, study of virus Herpes simplex.


RESULTS
The percentage of positive samples was 22.60%. The isolated microorganisms were: U. urealyticum 7.61%, N. gonorrhoeae 6.33%, C. trachomatis 4.81%, M. hominis 0.24%, H. parainfluenzae 1.76%, H. influenzae 1.12%, Candida spp 0.48%, S. pyogenes 0.16% and Herpes virus simplex (2) 0.08%. Two or more microorganisms were isolated in 1.68%. The percentage of positive samples in 2003 was 17.41% and N. gonorrhoeae the most frequent microorganism (6.22%). In 2004 was 25.57% and the most frequent U. urealyticum (10.18%). In 2005 the 24.50% of the samples were positive and U. urealyticum the most frequent (7.92%). The 79.41% of N. gonorrhoeae were susceptible to all antibiotics tested. It is not found resistance to ceftriaxone, claritromicine and amoxicilline/clavulanic acid. The 11.76% were betalactamase- producing. The 26.47% of Haemophilus spp. were betalactamase- producing and all strains were susceptible to cefotaxime.


CONCLUSIONS
The isolated microorganisms most frequently were: U. urealyticum, N. gonorrhoeae and C. trachomatis. There is an increase of 7% of prevalence between the years 2003 and 2005. Ceftriaxone, claritromicine and amoxicilline/clavulanic acid were susceptible to all the strains studied and cefotaxime to all Haemophilus spp.
Orellana
M A
MA
Laboratorio C.E.P., Pontones, Area 11, Madrid. m.a.orellana@jv.e.telefonica.net
Gómez
M l
Ml
Sánchez
M T
MT
Fernández-Chacón
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000175:diagnosis / Q000453:epidemiology; D002690:Chlamydia Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D002692:Chlamydia trachomatis / Q000187:drug effects / Q000302:isolation & purification; D003430:Cross-Sectional Studies; D024901:Drug Resistance, Multiple, Bacterial; D006069:Gonorrhea / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006561:Herpes Simplex / Q000175:diagnosis / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009344:Neisseria gonorrhoeae / Q000187:drug effects / Q000302:isolation & purification; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology; D014505:Urban Population / Q000706:statistics & numerical data; D016869:Ureaplasma Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D016990:Ureaplasma urealyticum / Q000187:drug effects / Q000302:isolation & purification; D014526:Urethritis / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D055815:Young Adult
D000900:Anti-Bacterial Agents